DBV Technologies S.A. (DBVT) Stock

About DBV Technologies S.A.

DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.

DBV Technologies S.A. is headquartered in FR.

DBV Technologies S.A. (DBVT) stock trades at $15.84 with a market capitalization of $378.92M. The stock is valued at a negative price-to-earnings (P/E) ratio of -3.27, reflecting a net loss over the last twelve months, price-to-book of 6.53, price-to-sales of 595.53. Over the past 52 weeks the stock has ranged between $8.51 and $26.19, and currently trades 39.5% below its 52-week high.

On profitability, DBV Technologies S.A. generates a return on equity (ROE) of -130.06% (negative, reflecting a net loss), return on capital employed of -80.15%, an operating margin of -5311.11%.

Official website: www.dbv-technologies.com

DBV Technologies S.A. by the numbers, 2016–2025

Between 2016 and 2025 DBV Technologies S.A. reported revenue of $8.0M rising to $0, a change of -100.0% across 10 years. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-147.0M.

On a trailing twelve-month basis to Mar '26, revenue is $0 and net profit $-168.0M.

Borrowings rose from $5.0M to $22.0M, cash on hand is $229.2M, cash from operations was $-121.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -142.0% over five years, and was -87.0% in the most recent year.

The share price itself has compounded at 8.6% a year over five years, 68.9% over three, 61.5% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

DBV Technologies S.A. (DBVT) — frequently asked questions